GSK3B (Glycogen Synthase Kinase 3 Beta)

Pharmacological disruption of this N-terminal interaction by streptonigrin, in combination with standard chemotherapy, extended overall survival in a xenograft model of ovarian cancer. This study identified TGase 2 as a pivotal regulator of EMT-driven metastasis and drug resistance.

Mitogen-Activated Protein Kinases (MAPKs), cytosol, kinase binding, and regulation of apoptotic processes represent the key signaling pathways, cellular components, molecular functions, and biological processes involved. The results of the current study demonstrate that GSK3β and CypA contribute to clarifying the mechanisms underlying AD pathophysiology in cellular studies related to this disorder.

Additionally, BBR preserved cellular proliferation, decreased TUNEL+ apoptotic cells and the inflammatory response in SMG tissues and organoids in HNR-induced xerostomia models. In conclusion, this study demonstrates that BBR can increase saliva secretion in healthy and HNR mice, indicating its potentiality for the treatment of radiation-induced xerostomia.

Our findings revealed GSK3B, RELA, CDKN1A, and PCK2 as central regulators shared across multiple stages of the disease. Notably, several of these genes had not previously been included in established MM gene sets, highlighting them as prime candidates for biomarkers and drug targets.

Combination treatment with cisplatin yielded synergistic effects in A549 (CI = 0.83) and H460 (CI = 0.94) cells, but antagonistic effects in H23 cells (CI = 1.32). These findings identify 2,3'-dihydroxy-5'-methoxystilbene as a selective AKT-targeting stilbene with promising anticancer potential and context-dependent chemosensitizing activity in NSCLC cells.

Our findings provide strong evidence that Plumbagin significantly reduced neuroinflammation, provided neuroprotective support, and alleviates cognitive impairment, as demonstrated through in-silico and in-vivo analyses.

Multivariate analysis confirmed functional interactions between the GABAergic and Wnt pathways.GSK-3β appears to integrate GABAergic and Wnt/β-catenin signaling and may serve as a robust, independent biomarker of metastatic risk in HNSCC. Although preliminary, these findings support the potential clinical value of GSK-3β and warrant validation in larger, multicenter cohorts before considering its incorporation into risk stratification models or targeted therapeutic strategies.

A recent study reported a series of dual selective nanomolar inhibitors based on structure-activity relationship (SAR) optimization. In-depth profiling of the lead compound's neuroprotective and modulatory properties establishes a foundation for the development of next-generation neuroregenerative therapeutics.

We have identified a highly aggressive GSK3βhigh/NFATc1high subtype that predicts early recurrence, poor survival and cisplatin resistance in PDAC. This subtype reveals new treatment vulnerabilities suggesting that patients with PDAC may benefit from stratification-based tailored treatment strategies.

This supports the broader anticancer and Akt-inhibitory potential of DM2. This study is the first to demonstrate that DM2 enhances anticancer synergy by suppressing O-GlcNAcylation and Akt signaling, highlighting its potential as a novel chemotherapy adjuvant.

We found a positive correlation between the mRNA expressions of GSK3β and S6K1, showing their coordinated transcription. We also showed that their simultaneous low expression is unfavorable for TNBC patients and could possibly be used as a predictive marker.

Self-reported race and ethnicity were associated with oral potential malignant disorder/oral cancer. Future studies using ancestry informative markers can confirm these findings.